INS and Hypoglycemia: These findings are in line with the concept of the ability of the DPP-4 inhibitor vildagliptin to improve insulin and glucagon imbalance, thereby preventing development of hypoglycemia and decreasing the levels of fasting and postprandial glycemia (28,29).